key: cord-0985444-t66alujn
authors: Marimuthu, Yamini; Kunnavil, Radhika; Satyanarana, N.; Anil, N.S.; Kumar, Jeetendra; Sharma, Nandini; Chopra, Kamal Kishore
title: Clinical presentation and mortality risk factors for COVID-19 among diabetic patients in a tertiary care center in South India
date: 2021-08-14
journal: Indian J Tuberc
DOI: 10.1016/j.ijtb.2021.08.015
sha: db71715378ad83b09716f3225bd6a979acfdbc87
doc_id: 985444
cord_uid: t66alujn

BACKGROUND: Non-communicable diseases (NCD) like hypertension, diabetes, cardiovascular and cerebrovascular diseases are the most common comorbidities among COVID-19 patients. The clinical presentation and mortality pattern of COVID-19 are different for patients with comorbidities and without comorbidities. OBJECTIVE: To determine the clinical presentation of COVID-19 and risk factors for COVID-19 mortality among diabetic patients in a tertiary care hospital in South India. METHODS: A record-based longitudinal study was conducted by reviewing the case records of COVID-19 patients admitted for treatment from June 2020 to September 2020 in a tertiary care centre in South India. Potential risk factors for COVID-19 mortality were analysed using univariate binomial logistic regression, generalized linear models (GLM) with the Poisson distribution. Survival curves were made using the Kaplan-Meier method. RESULTS: Out of 200 COVID-19 patients with diabetes with a mean (SD) age of 56.1 (11.8) years, 61% were men. The median survival time was slightly lesser in male COVID-19 patients (15 days) as compared to female patients (16 days). The risk of mortality among COVID-19 patients with diabetes is increased for patients who presented with breathlessness (aRR=4.5 (95% CI: 2.3-8.8)), had positive history of smoking (aRR=1.9 (95% CI: 1.1-3.8)), who had CKD (aRR=1.8 (95% CI: 1.1-2.8)) and who had cardiac illness (aRR=1.6 (95% CI: 0.9-2.7)). CONCLUSION: Diabetes patients with COVID-19 need to be given additional care and monitoring especially if they present with breathlessness, positive history of smoking, cardiac illness and, CKD. Public health campaigns and health education activities to control smoking is needed to reduce the COVID-19 mortality in diabetes patients.

Results: Out of 200 COVID-19 patients with diabetes with a mean (SD) age of 56.1 (11.8) years, 61% were men. The median survival time was slightly lesser in male COVID-19 patients (15 days) as compared to female patients (16 days) . The risk of mortality among COVID-19 patients with diabetes is increased for patients who presented with breathlessness (aRR=4.5 (95% CI: 2.3-8.8)), had positive history of smoking (aRR=1.9 (95% CI: 1.1-3.8)), who had CKD (aRR=1.8 (95% CI: 1.1-2.8)) and who had cardiac illness (aRR=1.6 (95% CI: 0.9-2.7)).

Conclusion: Diabetes patients with COVID-19 need to be given additional care and monitoring especially if they present with breathlessness, positive history of smoking, cardiac illness and, CKD. Public health campaigns and health education activities to control smoking is needed to reduce the COVID-19 mortality in diabetes patients. India is undergoing the epidemiological transition with a dual burden of diseases, both communicable and non-communicable diseases contributing to morbidity. 5 Diabetes is one of the common NCDs contributing to the dual burden of diseases with 65·0 million Indians having diabetes in 2016. 6 With the increasing prevalence of diabetes in India among adults aged 20 years or older from 5·5% in 1990 to 7·7% in 2016 6 and the worse prognosis of COVID-19 among diabetic patients 7 , the impact of the COVID-19 pandemic in India will be abominable.

Patients with diabetes who have compromised immunity and a poorly regulated inflammatory cytokine storm might be the possible mechanisms for severe COVID-19 disease among diabetes patients. 8 Increased glycation of ACE2 and reduced ACE2 in diabetic patients with poor control of glycemic status explains the increased susceptibility to severe ARDS and lung damage in COVID-19 patients. 9 Diabetic-COVID-19 patients with other comorbid health conditions like hypertension, ischemic heart diseases, obesity were more likely to have severe disease, hospitalization, and death. 7 A study in Wuhan has shown that diabetic patients with COVID-19 had higher odds of J o u r n a l P r e -p r o o f 3 Intensive care unit (ICU) admission and death. 10 An Italian study showed that 8.9% of the COVID-19 admitted had diabetes. Another British study has shown that the risk of mortality was more among COVID-19 patients with uncontrolled diabetes with a hazard ratio of 2·36

[95% CI 2·18-2·56]. 11 The literature related to the clinical presentation of COVID-19 among diabetes patients in India is very limited. With this background, this study was conducted to assess the clinical presentation of COVID-19 and risk factors for COVID-19 mortality among diabetic patients in a tertiary care hospital in South India.

A record-based cross-sectional study was conducted by reviewing the case sheets of COVID-19 patients admitted for treatment in the tertiary care center in Bangalore, India. Since June 2020, this center was designated as Dedicated COVID Hospital (DCH) by the Government of Karnataka (GoK) and standard care is being free of cost to the COVID-19 patients.

The clinical and socio-demographic details were collected from the case records maintained in the hospital. The data collected were entered in MS Excel. The anonymity and confidentiality of the information collected were maintained throughout the study. During the period from June 2020 till September 2020, 854 records of confirmed COVID-19 cases were analyzed. Out of them, there were 200 COVID-19 patients with diabetes comorbidity which were included in the current study. Patients were followed from the date of admission till the date of discharge/death from the hospital.

The variables included in the study are age, sex, the presence of symptoms like fever, cough, breathlessness, sore throat, loose stools chest pain, headache, myalgia. The details like the history of travel, contact, smoking, alcohol consumption were also included in the study. The presence of other comorbidities like hypertension, chronic kidney disease (CKD), respiratory diseases, malignancies, tuberculosis, and hypothyroidism was also collected from the case records. After the period of stay in the hospital, the outcome of the patients was categorized 15 The continuous variables were summarized using mean (SD) or median (interquartile range (IQR)) based on the distribution of data. Other categorical variables were summarized using frequencies and proportions. Chi-square test and Fischer's exact tests are used to assess the statistical significance of association between the categorical variables.

Binomial logistic regression was used to do the univariate analysis to determine the factors associated with mortality among diabetic patients with COVID-19. Relative risk (RR) with a 95% confidence interval (95% CI) was used to express the strength of association. A generalized linear model (GLM) with Poisson distribution was used for multivariate analysis and adjusted relative risk (aRR) with 95% CI was calculated. The variables which were significantly associated with the outcome (p-value < 0.05) in the univariate analysis were J o u r n a l P r e -p r o o f 5 included in the multivariate analysis. A p-value less than 0.05 was considered statistically significant. Kaplan -Meier method was used to plot the survival curves and the survival distributions between the groups were tested using the Log-rank test.

The ethical approval to conduct the study was taken from the Institutional Ethics Committee and due permissions were taken from the authorities. The anonymity and confidentiality of the data were maintained throughout the study.

In total 200 COVID-19 patients with diabetes were included in the study whose mean (SD) age was 56.1 (11.8) years. Out of 200 study participants, 78 (39%) were women and 122 (61%) were men. The symptoms with which COVID-19 patients with diabetes presented were fever (59.5%), cough (48%), difficulty in breathing (42%), myalgia (26.5%), sore throat (3%), headache (11%), loose stools (3.5%), loss of taste/smell (5%) and chest pain (5%). The History of contact with a positive case of COVID-19 was present in 38 (19%) and history of travel to a foreign country was present in 23 (11.5%) of the study participants. The comorbidities present in the COVID-19 with diabetes were hypertension (56.5%), ischemic heart disease (9.5%), hypothyroidism (7%), CKD (3.5%), respiratory diseases like chronic obstructive pulmonary disease (COPD), and asthma (3%), tuberculosis (3.0%) and malignancy (1.5%).

Our results showed that the risk of death due to COVID-19 among diabetes patients increased by RR=5.2 (95% CI: 2.7-9.9) times among those who presented with breathlessness as compared to those who did not have breathlessness [ Table 1 ]. Diabetic COVID-19 patients J o u r n a l P r e -p r o o f 6 with a history of smoking had a 3.3 (RR=3.3, 95% CI: 1.7-6.1) times increased risk of mortality as compared to non-smokers and this association was statistically significant [ Figure 2 ]. COVID-19 Patients with diabetes and CKD had 3.2 times (RR=3.2, 95% CI: 1.8- Table 2 ]. Similarly, COVID-19 patients with diabetes and cardiac illness had 2.1 times (RR=2.1, 95% CI: 1.2-3.8) increased risk of mortality and the association was statistically significant.

In the multivariate analysis, the variables which were significantly associated with mortality in the univariate analysis like presenting with breathlessness, history of smoking, CKD, cardiac illness were included in the model. After adjusting for other variables included in the model, the risk of mortality among COVID-19 patients with diabetes is increased for patients who presented with breathlessness (aRR=4.5 (95% CI: 2.3-8.8)), had a positive history of smoking (aRR=1.9 (95% CI: 1.1-3.8)), who had CKD (aRR=1.8 (95% CI: 1.1-2.8)) and who had a cardiac illness (aRR=1.6 (95% CI: 0.9-2.7)). These associations were also statistically significant in multivariate analysis [ Table 3 ].

Our analysis has identified that patients presenting with breathlessness, patients with comorbidities CKD and cardiac illness, positive history of smoking were significantly associated with mortality due to COVID among diabetes patients. A systematic review and meta-analysis by Galbadage T et al showed that gender was significantly associated with mortality with the male sex having a high risk of death due to COVID-19. 16 But the current study depicted that among COVID-19 patients with diabetes as comorbidity, gender is not significantly associated with mortality [ Figure 1 ]. This result is similar to another study done in the UK which also showed that gender was not significantly associated with mortality among diabetes patients with COVID-19. 17 Our study showed that patients presenting with breathlessness had 4 times increased risk of J o u r n a l P r e -p r o o f 7 mortality even after adjusting for other confounding variables which similar to findings among non-diabetic COVID-19 patients. [18] [19] [20] Smoking increased the risk of death by 1.9 times among COVID-19 patients with diabetes which is similar to other studies as evinced from a systematic review and meta-analysis by Salah HM et al. 17 Smoking increases the expression of Angiotensin-Converting Enzyme-2 (ACE2) which is also linked to the effects of COVID-19. 21 Smoking and COVID-19 cause endothelial injury, hypercoagulable state, and disturbed immune system which explain the increased risk of mortality among COVID-19 patients. 22, 23 The current study showed that having the second comorbidity like cardiac diseases and CKD along with diabetes increased the risk of mortality among COVID-19 patients by 1.6 times and 1.8 times respectively. ACE2 dependent pathway in the kidney is affected by the SARS-CoV-2 virus leading to acute kidney injury and death which might be the reason for the increased mortality among COVID-19 patients with CKD. 24 The effects of the SARS-CoV-2 virus on the cardiovascular system can be explained in many aspects. It anchors on the transmembrane ACE2 to enter the host cells including type 2 pneumocytes, macrophages, endothelial cells, pericytes, and cardiac myocytes. 25 The virus can also destabilize atherosclerotic plaques which lead to the development of acute coronary syndromes. 25 The above mechanisms lead to inflammation, multi-organ failure, and death.

Strengths and limitations: Our study has a few strengths. We analyzed the data from a large number of COVID-19 patients with diabetes with appropriate statistical analysis. Our study has few limitations. This is a record-based study from a tertiary hospital, so the generalizability of the study results needs to be done with caution. The duration of symptoms 

World Health Organization. COVID-19 Weekly Epidemiological Update 22

Ministry of Health and Family Welfare Government of India

Comorbidity and its Impact on Patients with COVID-19. SN Compr Clin Med

A meta-analysis of 2019 novel corona virus patient clinical characteristics and comorbidities. Res Sq

Understanding epidemiological transition in India. Glob Health Action

The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Heal

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Endocrine and metabolic link to coronavirus infection

COVID-19, diabetes mellitus and ACE2: The conundrum

Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients with Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care

OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv

National Centre for Disease Control. The updated case definitions and contactcategorisation

World Health Organization. Global Adult Tobacco Survey (GATS) Indicator Guidelines: Definition and Syntax

Alcohol use

StataCorp. Stata Statistical Software: Release 14

Systematic review and meta-analysis of sex-specific COVID-19 clinical outcomes

Diabetes and COVID-19-Related Mortality in Women and Men in the UK Biobank: Comparisons With Influenza/ Pneumonia and Coronary Heart Disease. Diabetes Care

Presenting Symptoms and Predictors of Poor Outcomes Among 2,184 Patients with COVID-19 in Lagos State

A study on the predictors of disease severity of COVID-19

Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis

Smoking Doubles the Mortality Risk in COVID-19: A Meta-Analysis of Recent Reports and Potential Mechanisms

Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review

Tobacco smoking increases the lung gene expression of ACE2, the Receptor of SARS-CoV-2

Covid-19 in patients with kidney disease

COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options